Maxim Group analyst Michael Okunewitch initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and announces Price Target of $24.
Related Posts
Wedbush Reiterates Outperform on Amazon.com, Maintains $180 Price Target
Wedbush analyst Scott Devitt reiterates Amazon.com (NASDAQ:AMZN) with a Outperform and maintains $180 price target.
How Is The Market Feeling About Stryker?
Stryker’s (NYSE:SYK) short percent of float has risen 14.29% since its last report. The company recently reported that it has…